Incyte reported $3.09 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 1.98 2.26 Nov/03
FY2026Q2 Jun/2026 3.09 1.99 1.57 Jul/28
FY2026Q1 Mar/2026 1.81 1.42 1.16 Apr/28
FY2025Q4 Dec/2025 1.80 1.93 1.43 Feb/10
FY2025Q3 Sep/2025 2.26 1.58 1.07 Oct/28




Eps Change Date
Acadia Pharmaceuticals USD 0.18 0.16 Jun/2026
Agenus USD 1.02 1.32 Mar/2026
Agios Pharmaceuticals USD -1.69 0 Jun/2026
Alnylam Pharmaceuticals USD 1.84 0.15 Jun/2026
Amgen USD 6.29 1.14 Jun/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
Biogen USD 3.6 0.03 Jun/2026
BioMarin Pharmaceutical USD 1.2 0.44 Jun/2026
Bristol-Myers Squibb USD 2.04 0.46 Jun/2026
Eli Lilly USD 8.38 0.17 Jun/2026
Exelixis USD 0.91 0.04 Jun/2026
Gilead Sciences USD -6.75 8.78 Jun/2026
Incyte USD 3.09 1.28 Jun/2026
Ionis Pharmaceuticals USD -0.69 0.13 Jun/2026
MacroGenics USD -0.58 0.36 Mar/2026
Merck USD -0.13 1.15 Jun/2026
Moderna USD -1.97 1.43 Jun/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Neurocrine Biosciences USD 2.85 0.91 Jun/2026
Novartis USD 2.41 0.42 Jun/2026
Novartis USD 1.99 0.45 Mar/2026
Pfizer USD 0.77 0.02 Jun/2026
PTC Therapeutics USD 0.92 0.95 Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 14.29 4.82 Jun/2026
Sarepta Therapeutics USD 0.64 2.52 Jun/2026
Ultragenyx Pharmaceutical USD -0.9 0.94 Jun/2026
Vertex Pharmaceuticals USD 4.73 0.26 Jun/2026